RDY Quote, Financials, Valuation and Earnings

HDFC Bank has a net margin of 18.74% compared to Dr Reddy's Laboratories's net margin of 25.7%. Dr Reddy's Laboratories's return on equity of 18.27% beat HDFC Bank's return on equity of 12.02%.

Dr Reddy's Laboratories has a consensus price target of $14.96, signalling upside risk potential of 3.33%. On the other hand HDFC Bank has an analysts' consensus of $86.23 which suggests that it could grow by 14.54%. Given that HDFC Bank has higher upside potential than Dr Reddy's Laboratories, analysts believe HDFC Bank is more attractive than Dr Reddy's Laboratories.

Dr Reddy's Laboratories has a beta of 0.333, which suggesting that the stock is 66.713% less volatile than S&P 500. In comparison HDFC Bank has a beta of 0.639, suggesting its less volatile than the S&P 500 by 36.068%.

Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.66%. HDFC Bank offers a yield of 1.95% to investors and pays a quarterly dividend of $0.78 per share. Dr Reddy's Laboratories pays 11.78% of its earnings as a dividend. HDFC Bank pays out 23.47% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr Reddy's Laboratories quarterly revenues are $982M, which are smaller than HDFC Bank quarterly revenues of $8.5B. Dr Reddy's Laboratories's net income of $184M is lower than HDFC Bank's net income of $2.2B. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 22.04x while HDFC Bank's PE ratio is 23.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.14x versus 8.66x for HDFC Bank. Usually stocks with elevated PS ratios are considered overvalued.

ICICI Bank has a net margin of 18.74% compared to Dr Reddy's Laboratories's net margin of 23.81%. Dr Reddy's Laboratories's return on equity of 18.27% beat ICICI Bank's return on equity of 17.09%.

Dr Reddy's Laboratories has a consensus price target of $14.96, signalling upside risk potential of 3.33%. On the other hand ICICI Bank has an analysts' consensus of $40.18 which suggests that it could grow by 20.97%. Given that ICICI Bank has higher upside potential than Dr Reddy's Laboratories, analysts believe ICICI Bank is more attractive than Dr Reddy's Laboratories.

Dr Reddy's Laboratories has a beta of 0.333, which suggesting that the stock is 66.713% less volatile than S&P 500. In comparison ICICI Bank has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.726%.

Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.66%. ICICI Bank offers a yield of 0.72% to investors and pays a quarterly dividend of $0.24 per share. Dr Reddy's Laboratories pays 11.78% of its earnings as a dividend. ICICI Bank pays out 13.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr Reddy's Laboratories quarterly revenues are $982M, which are smaller than ICICI Bank quarterly revenues of $6.5B. Dr Reddy's Laboratories's net income of $184M is lower than ICICI Bank's net income of $1.6B. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 22.04x while ICICI Bank's PE ratio is 19.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.14x versus 4.90x for ICICI Bank. Usually stocks with elevated PS ratios are considered overvalued.

SS Innovations International has a net margin of 18.74% compared to Dr Reddy's Laboratories's net margin of -110.95%. Dr Reddy's Laboratories's return on equity of 18.27% beat SS Innovations International's return on equity of -76.16%.

Dr Reddy's Laboratories has a consensus price target of $14.96, signalling upside risk potential of 3.33%. On the other hand SS Innovations International has an analysts' consensus of -- which suggests that it could fall by --. Given that Dr Reddy's Laboratories has higher upside potential than SS Innovations International, analysts believe Dr Reddy's Laboratories is more attractive than SS Innovations International.

Dr Reddy's Laboratories has a beta of 0.333, which suggesting that the stock is 66.713% less volatile than S&P 500. In comparison SS Innovations International has a beta of -68.829, suggesting its less volatile than the S&P 500 by 6982.93%.

Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.66%. SS Innovations International offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr Reddy's Laboratories pays 11.78% of its earnings as a dividend. SS Innovations International pays out -- of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr Reddy's Laboratories quarterly revenues are $982M, which are larger than SS Innovations International quarterly revenues of $5.1M. Dr Reddy's Laboratories's net income of $184M is higher than SS Innovations International's net income of -$5.7M. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 22.04x while SS Innovations International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.14x versus 65.55x for SS Innovations International. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab has a net margin of 18.74% compared to Dr Reddy's Laboratories's net margin of -45.49%. Dr Reddy's Laboratories's return on equity of 18.27% beat Zai Lab's return on equity of -33.29%.

Dr Reddy's Laboratories has a consensus price target of $14.96, signalling upside risk potential of 3.33%. On the other hand Zai Lab has an analysts' consensus of $56.38 which suggests that it could grow by 67.96%. Given that Zai Lab has higher upside potential than Dr Reddy's Laboratories, analysts believe Zai Lab is more attractive than Dr Reddy's Laboratories.

Dr Reddy's Laboratories has a beta of 0.333, which suggesting that the stock is 66.713% less volatile than S&P 500. In comparison Zai Lab has a beta of 0.989, suggesting its less volatile than the S&P 500 by 1.125%.

Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.66%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr Reddy's Laboratories pays 11.78% of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr Reddy's Laboratories quarterly revenues are $982M, which are larger than Zai Lab quarterly revenues of $106.5M. Dr Reddy's Laboratories's net income of $184M is higher than Zai Lab's net income of -$48.4M. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 22.04x while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.14x versus 8.16x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.